IfW

Attorney Docket No. 60020830-0004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of:) Group Art Unit: 1656
Tze Chein Wun) Examiner: Holly G. Schnize
Application No. 10/516,908)
Filed: March 17, 2005) Confirmation No.: 5630
For: NOVEL RECOMBINANT ANTICOAGULANT PROTEINS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT CITED IN A COMMUNICATION FROM A FOREIGN PATENT OFFICE

Each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. § 1.97(e)(1). A copy of the Supplementary European Search Report citing the references, mailed on April 26, 2006, is enclosed.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

10/516,908 (60020830-0004) Transmittal of Information Disclosure Statement Page 2

. . . .

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner.

Applicant does not believe any fees are due in connection with this submission. However, any applicable fees can be charged to Deposit Account No. 19-3140.

Respectfully submitted,

Dated: 6/27/2006

By:

Registration No. 42,927

SONNENSCHEIN NATH & ROSENTHAL LLP

P.O. Box 061080

Wacker Drive Station, Sears Tower

Chicago, Illinois 60606-1080

314.259.5867

23199737\V-1

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1983, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/RTO HAN S. A core		Complete if Known			
Substitute for form 1449B/ 10 JUN 3-0 2006			8/	Application Number	10/516,908
INFORMATION DISCLOSURE STATEMENT BY AFTURANT		Filing Date	March 17, 2005		
		First Named Inventor	Tze Chein Wun		
				Art Unit	1656
	(use as	many shee	ts as necessary)	Examiner Name	Holly G. Schnizer
Sheet	1	of	1	Attorney Docket No.	60020830-0004

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te .
	54	EP 0965597	12-22-1999	Mochida Pharmaceutical Co., Ltd.	-	
	55	WO 88/07676	10-06-1998	Boehringer Ingelheim International GmbH		

OTHER ITEMS - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials* Cite No. I Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s publisher, city and/or country where published.		T ²		
	56	EMBL Database Number A01769 for "DNA Sequence (gaa) for Vascular Anticoagulating Protein," 1993, 2 pages retrieved from http://www.ebi.ac.uk/cgi-bin/emblfetch?style=html&id=A01769& Submit=Go in 2006.		
	57	CHEN et al., "Fusion Proteins Comprising Annexin V and Kunitz Protease Inhibitors are Highly Potent Thrombogenic Site-Directed Anticoagulants," Blood, 2005, pp. 3902-3909, Vol. 10.		
	58	LEE et al., "Protein Bifunctional Anticoagulants: Kunitz Domain-Tissue Factor Fusion Protein," Biochem., 1997, pp. 5607-5611, Vol. 36.		

Examiner	Date	
Signature	Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1540, Alexandria, VA 22113-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.